Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Johnson & Johnson...

    Johnson & Johnson profit beats, lifts forecast on cancer drug demand

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-10-17T09:10:53+05:30  |  Updated On 16 Aug 2021 1:31 PM IST

    Johnson & Johnson reported slightly better-than-expected third quarter profit and raised its full-year forecast on Tuesday as increased demand for cancer drugs and immune disorder treatments powered strong results for its pharmaceutical unit.


    Shares of the healthcare conglomerate were up 2.3 percent at $137 in morning trading after it raised its adjusted 2018 earnings forecast to a range of $8.13 to $8.18 per share from a prior view of $8.07 to $8.17.


    Solid prescription drug sales helped offset continued disappointment in the medical devices segment. Executives on a conference call said that business would start to grow in-line or better than the market by 2020.


    "We are not satisfied with the performance in medical devices," Chief Financial Officer Joseph Wolk said after the unit's quarterly sales missed Wall Street estimates.


    Pricing pressure has impacted all categories in orthopedics, the company said, adding that it will consider both transformative acquisitions and smaller, tuck-in deals to support the business.


    The company has been selling off certain businesses, such as diabetes care devices, to focus on better performing units and the development of new products.


    Overall sales rose 3.6 percent to $20.35 billion in the quarter, exceeding analysts' average estimate of $20.05 billion, according to Refinitiv data.


    Pharmaceuticals sale rose 6.7 percent to $10.35 billion, fueled by double-digit sales growth for prostate cancer drug Zytiga and Stelara for Chrohn's disease and psoriasis


    Zytiga sales surged 43 percent to $958 million, blowing past the consensus estimate of $795 million, according to Barclays. Stelara sales jumped 16.5 percent to $1.31 billion, above expectations of about $1.27 billion.


    Sales of rheumatoid arthritis drug Remicade fell 16.3 percent to $1.38 billion due to increasing competition from cheaper biosimilar versions.


    Newer blood cancer drug Darzalex brought in sales of $498 million, falling short of lofty Wall Street estimates of about $510 million.


    Medical device sales were down 0.2 percent at $6.59 billion, while consumer products sales rose 1.8 percent to $3.42 billion, helped by the U.S. relaunch of the Johnson's baby brand.


    Excluding items, the company earned $2.05 per share, edging past analysts' average forecasts by 2 cents.


    Wolk said on Tuesday that while J&J was supportive of more transparency in drug pricing, the company does not believe a Trump administration proposal for requiring the list price of medicines at the end of television ads would be helpful.


    He said including those prices in commercials could be somewhat confusing and "act as a deterrent to good responsible healthcare."

    blood cancercancer drug demandcancer drugscheaper biosimilar versionsdiabetes care devicesimmune disorderJohnson & JohnsonJoseph Wolkorthopedicspharmaceutical unitRefinitiv dataWall Street estimatesZytiga

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok